Psoriasis comorbidities: complications and benefits of immunobiological treatment
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Anais brasileiros de dermatologia (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962016000600781 |
Resumo: | Abstract During the last decade, different studies have converged to evidence the high prevalence of comorbidities in subjects with psoriasis. Although a causal relation has not been fully elucidated, genetic relation, inflammatory pathways and/or common environmental factors appear to be underlying the development of psoriasis and the metabolic comorbidities. The concept of psoriasis as a systemic disease directed the attention of the scientific community in order to investigate the extent to which therapeutic interventions influence the onset and evolution of the most prevalent comorbidities in patients with psoriasis. This study presents scientific evidence of the influence of immunobiological treatments for psoriasis available in Brazil (infliximab, adalimumab, etanercept and ustekinumab) on the main comorbidities related to psoriasis. It highlights the importance of the inflammatory burden on the clinical outcome of patients, not only on disease activity, but also on the comorbidities. In this sense, systemic treatments, whether immunobiologicals or classic, can play a critical role to effectively control the inflammatory burden in psoriatic patients. |
id |
SBD-1_2ef1a578cb16de491f2c0b0bb421158f |
---|---|
oai_identifier_str |
oai:scielo:S0365-05962016000600781 |
network_acronym_str |
SBD-1 |
network_name_str |
Anais brasileiros de dermatologia (Online) |
repository_id_str |
|
spelling |
Psoriasis comorbidities: complications and benefits of immunobiological treatmentComorbidityMetabolic Syndrome XPsoriasisTumor necrosis factor-alphaAbstract During the last decade, different studies have converged to evidence the high prevalence of comorbidities in subjects with psoriasis. Although a causal relation has not been fully elucidated, genetic relation, inflammatory pathways and/or common environmental factors appear to be underlying the development of psoriasis and the metabolic comorbidities. The concept of psoriasis as a systemic disease directed the attention of the scientific community in order to investigate the extent to which therapeutic interventions influence the onset and evolution of the most prevalent comorbidities in patients with psoriasis. This study presents scientific evidence of the influence of immunobiological treatments for psoriasis available in Brazil (infliximab, adalimumab, etanercept and ustekinumab) on the main comorbidities related to psoriasis. It highlights the importance of the inflammatory burden on the clinical outcome of patients, not only on disease activity, but also on the comorbidities. In this sense, systemic treatments, whether immunobiologicals or classic, can play a critical role to effectively control the inflammatory burden in psoriatic patients.Sociedade Brasileira de Dermatologia2016-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962016000600781Anais Brasileiros de Dermatologia v.91 n.6 2016reponame:Anais brasileiros de dermatologia (Online)instname:Sociedade Brasileira de Dermatologia (SBD)instacron:SBD10.1590/abd1806-4841.20165080info:eu-repo/semantics/openAccessCarvalho,André Vicente Esteves deRomiti,RicardoSouza,Cacilda da SilvaPaschoal,Renato SorianiMilman,Laura de MattosMeneghello,Luana Pizarroeng2017-01-06T00:00:00Zoai:scielo:S0365-05962016000600781Revistahttp://www.anaisdedermatologia.org.br/https://old.scielo.br/oai/scielo-oai.phpabd@sbd.org.br||revista@sbd.org.br1806-48410365-0596opendoar:2017-01-06T00:00Anais brasileiros de dermatologia (Online) - Sociedade Brasileira de Dermatologia (SBD)false |
dc.title.none.fl_str_mv |
Psoriasis comorbidities: complications and benefits of immunobiological treatment |
title |
Psoriasis comorbidities: complications and benefits of immunobiological treatment |
spellingShingle |
Psoriasis comorbidities: complications and benefits of immunobiological treatment Carvalho,André Vicente Esteves de Comorbidity Metabolic Syndrome X Psoriasis Tumor necrosis factor-alpha |
title_short |
Psoriasis comorbidities: complications and benefits of immunobiological treatment |
title_full |
Psoriasis comorbidities: complications and benefits of immunobiological treatment |
title_fullStr |
Psoriasis comorbidities: complications and benefits of immunobiological treatment |
title_full_unstemmed |
Psoriasis comorbidities: complications and benefits of immunobiological treatment |
title_sort |
Psoriasis comorbidities: complications and benefits of immunobiological treatment |
author |
Carvalho,André Vicente Esteves de |
author_facet |
Carvalho,André Vicente Esteves de Romiti,Ricardo Souza,Cacilda da Silva Paschoal,Renato Soriani Milman,Laura de Mattos Meneghello,Luana Pizarro |
author_role |
author |
author2 |
Romiti,Ricardo Souza,Cacilda da Silva Paschoal,Renato Soriani Milman,Laura de Mattos Meneghello,Luana Pizarro |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Carvalho,André Vicente Esteves de Romiti,Ricardo Souza,Cacilda da Silva Paschoal,Renato Soriani Milman,Laura de Mattos Meneghello,Luana Pizarro |
dc.subject.por.fl_str_mv |
Comorbidity Metabolic Syndrome X Psoriasis Tumor necrosis factor-alpha |
topic |
Comorbidity Metabolic Syndrome X Psoriasis Tumor necrosis factor-alpha |
description |
Abstract During the last decade, different studies have converged to evidence the high prevalence of comorbidities in subjects with psoriasis. Although a causal relation has not been fully elucidated, genetic relation, inflammatory pathways and/or common environmental factors appear to be underlying the development of psoriasis and the metabolic comorbidities. The concept of psoriasis as a systemic disease directed the attention of the scientific community in order to investigate the extent to which therapeutic interventions influence the onset and evolution of the most prevalent comorbidities in patients with psoriasis. This study presents scientific evidence of the influence of immunobiological treatments for psoriasis available in Brazil (infliximab, adalimumab, etanercept and ustekinumab) on the main comorbidities related to psoriasis. It highlights the importance of the inflammatory burden on the clinical outcome of patients, not only on disease activity, but also on the comorbidities. In this sense, systemic treatments, whether immunobiologicals or classic, can play a critical role to effectively control the inflammatory burden in psoriatic patients. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016-12-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962016000600781 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962016000600781 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/abd1806-4841.20165080 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Dermatologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Dermatologia |
dc.source.none.fl_str_mv |
Anais Brasileiros de Dermatologia v.91 n.6 2016 reponame:Anais brasileiros de dermatologia (Online) instname:Sociedade Brasileira de Dermatologia (SBD) instacron:SBD |
instname_str |
Sociedade Brasileira de Dermatologia (SBD) |
instacron_str |
SBD |
institution |
SBD |
reponame_str |
Anais brasileiros de dermatologia (Online) |
collection |
Anais brasileiros de dermatologia (Online) |
repository.name.fl_str_mv |
Anais brasileiros de dermatologia (Online) - Sociedade Brasileira de Dermatologia (SBD) |
repository.mail.fl_str_mv |
abd@sbd.org.br||revista@sbd.org.br |
_version_ |
1752126421419950080 |